UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at http://www.ucl.ac.uk/finance/research/post_award/post_award_contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
 More search options
Mr Hirak Patra
Department of Surgical Biotechnology
UCL Division of Surgery and Interventional Science
Royal Free Campus | Rowland Hill Street
London
NW3 2PF
Appointment
  • Associate Professor in Nanomedicine and Regenerative Medicine
  • Department of Surgical Biotechnology
  • Div of Surgery & Interventional Sci
  • Faculty of Medical Sciences
Biography

 

Dr. Hirak K Patra is among the next generation of scientists with cross-discipline interests. He is an expert in nanomedicine and nanoscale biotechnology. He is a fellow (Jr, B1) at the Wolfson College at the University of Cambridge where he implemented his EU Marie Skłodowska Curie Individual European Fellowship. Dr. Patra completed his PhD with high standing reputation for his thesis work on “Synthetic nanoforms as designer and explorer for cellular events'' with several high rank publications and huge citations from University of Calcutta, well known for its fundamental education system with three Nobel Laureates in Asia. He moved to the Applied Physics Division of Linköping University with the prestigious Integrative Regenerative Medicine Fellowship at Sweden to work with the father of biosensor Prof. Anthony Turner at his Biosensors and Bioelectronics Center. His research interests across the discipline attract the attention of pioneer leading scientists and are awarded with several ‘Young Scientist’ categories globally. His personal dedication in the field and passion for innovation together with his skills and experience enable him to publish 4 PCT (Patent Cooperation Treaty) documents that is remarkable at his age.

Research Summary

Hirak’s Lab is exploring nanoscale science, technologies and materials for advanced healthcare applications. We are a group of enthusiastic researchers from diverse cross-disciplinary backgrounds united together to enjoy the fun in understanding nanoscience and exploring through dedicated scientific research. In our group we welcome and encourage disruptive innovation. We are involved in synthesis of new nanomaterials and chemistry for engineering their physical and chemical properties for biomedical applications.

The group is studying and developing molecular strategies that can help us to conceal a drug while transporting and program to deliver drugs step by step. We are involved in establishing tools for delivering the drug specifically up to the tertiary level (organelle). We are developing nano toolbox for disease specific requirements. The toolboxes are aimed to expand with theranostic capacity (capacity to combine diagnosis and therapy). Our current research interest includes but not limited to
 
Basic understanding:
Biochemical environment of drug resistance
Understanding strategies for non-invasive monitoring of nanomaterials
Addressing the macroscale physicochemical environment for drug resistance
 
We focus on understanding the basic biochemical and physicochemical environment and mechanism of drug resistance, and nanoscale physical properties that can help non-invasive monitoring of such environment.
 
Engineering:
Synthesis and application of ultra-small nanosystems
Surface engineering nanosurface for specific targeting
Biosynthesis of nanoparticle/exosome/ECV/microparticles
Designing molecules and biopolymers for specific stimuli response
Theranostic module (combined diagnostic and therapeutic component in a single platform)
 
Our engineering research aims to develop systematic and automated synthesis of ultra-small nanosystems, biosynthesis of nanoparticles (exosome, ECV, etc.), stimuli response materials, and theranostic modules (combined diagnostic and therapeutic components in a single platform) for biomedical applications.
 
Translation:
Nano-diagnostics
Medicated implants to combat with rejection
Developing Nanovaccine for better immunomodulation
Personalised exosome/ECV/microparticle based delivery system

Our combined research interests are translational endeavour. For example, developing nano-diagnostic systems, rejection-combating medicated implants, nanovaccine with enhanced immunomodulation, and personalised delivery systems (exosome, ECV, and microparticle).

Appointments
2018 – 2021 Fellow (Jr, B1) Wolfson College University of Cambridge, United Kingdom
2017 – 2019 Marie Curie Individual European Fellow Department of Chemical Engineering & Biotechnology University of Cambridge, United Kingdom
2016 – 2019 Assistant Professor (Biträdande Universitetslektor) Department of Clinical and Experimental Medicine Linkoping University, Sweden
2014 – 2016 First Research Engineer (Förste forskningsingenjör) Department of Clinical and Experimental Medicine Linkoping University, Sweden
2012 – 2014 Integrative Regenerative Medicine (IGEN) Fellow Biosensors and Bioelectronic Centre Linkoping University, Sweden
Please report any queries concerning the data shown on this page to https://www.ucl.ac.uk/hr/helpdesk/helpdesk_web_form.php
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by